Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study

Moreno-Pérez, Óscar; Merino, Esperanza; León-Ramírez, José-Manuel; Andrés, Mariano; Ramos, José Manuel; Arenas, Juan; Sánchez, Santos Asensio; Sánchez, R Henche; Ruiz-Torregrosa, Paloma; Galan, Irene; Scholz, Alexander; Amo, A. Del; González-de-la-Aleja, Pilar; Boix, Vicente; Gil, Joan

doi:10.1016/j.jinf.2021.01.004

Cited by 547 publications

(669 citation statements)

References 16 publications

Supporting

Mentioning

545

Contrasting

Unclassified

Order By: Relevance

“…Observational studies deriving from different populations (USA, Europe and Asia) revealed a variable proportion of persistent symptoms following SARS-CoV-2 infection (Table 1, Appendix Table 2). Early studies provided evidence of persistent COVID sequelae reporting short term outcomes covering the post-acute phase (4-12 weeks) of COVID-19 [8,13,17,[19][20][21][22][23]27]. Most recent publications present data from larger cohorts with longer follow-up periods (beyond 12 weeks) illustrating the multisystemic manifestations of the so called "long" or "chronic'' COVID [10,12,18].…”

Section: Epidemiologymentioning

confidence: 99%

“…Similarly, it is unknown if SARS-COV-2 infection exacerbates preexisting neuropathies (e.g., diabetic neuropathy) Long-lasting and disabling fatigue is another frequently reported symptom under the umbrella of long COVID (Table 2, Appendix Table 2) [162,163]. Based on recent cohort studies, the frequency of fatigue and/or muscular weakness at 6 months post-symptom onset can reach 60% [162,164,165]. Intensity can fluctuate, it is typically exacerbated by physical or mental effort, it seems to affect mostly young women although exact frequency is hard to ascertain due to reporting bias.…”

Section: Chronic Pain/chronic Fatiguementioning

confidence: 99%

“…Recently published cohort studies have reported symptoms from most body systems in following the acute disease phase reflecting its multi-systemic nature [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] (Table1, Appendix Table 2).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

Korompoki

Gavriatopoulou

Hicklen

et al. 2021

Journal of Infection

126

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Epidemiologymentioning

confidence: 99%

Section: Chronic Pain/chronic Fatiguementioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

Korompoki

Gavriatopoulou

Hicklen

et al. 2021

Journal of Infection

126

View full text Add to dashboard Cite

show abstract

“…Most studies refer to their patient recruitment in terms of recovery (e.g., "COVID-19 survivors" 56 or "discharged COVID-19 patients" 57 ) or clinical course (e.g., "medium-and long-term consequences" 58 or "delayed return to usual health" 59 ). A number of studies did refer to their participant groups using terms like "Long COVID", 13,[60][61][62][63][64][65][66][67][68] "post-acute COVID-19", 69,70 "post-COVID syndrome", 71 or "post-acute COVID-19 syndrome", 72 but these terms were not standardized among studies. A few studies 46,60 acknowledged the proposed distinction at 12 weeks post-infection between post-acute COVID-19 and chronic COVID-19, 37 but otherwise the definitions used typically did not refer to any proposed operationalizations of Long COVID.…”

Section: Literature Reviewmentioning

confidence: 99%

“…Here, 21 studies, including 20 published studies 14,47,52,56,58,59,63,66,72,73,[75][76][77]79,[92][93][94][95][96][97] and one preprint, 13 were chosen for the in-depth phenotypic analysis using HPO. A total of 154 different phenotypic abnormalities could be encoded using HPO terms.…”

Section: Ontological Analysis Of Literaturementioning

confidence: 99%

Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information

Rando

Bennett

Byrd

et al. 2021

Preprint

116

124

View full text Add to dashboard Cite

Since late 2019, the novel coronavirus SARS-CoV-2 has introduced a wide array of health challenges globally. In addition to a complex acute presentation that can affect multiple organ systems, increasing evidence points to long-term sequelae being common and impactful. As the worldwide scientific community forges ahead with efforts to characterize a wide range of outcomes associated with SARS-CoV-2 infection, the proliferation of available data has made it clear that formal definitions are needed in order to design robust and consistent studies of Long COVID that consistently capture variation in long-term outcomes. In the present study, we investigate the definitions used in the literature published to date and compare them against data available from electronic health records and patient-reported information collected via surveys. Long COVID holds the potential to produce a second public health crisis on the heels of the pandemic. Proactive efforts to identify the characteristics of this heterogeneous condition are imperative for a rigorous scientific effort to investigate and mitigate this threat.

show abstract

Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021

Hanson

Abbafati

Aerts

et al. 2022

JAMA

492

324

View full text Add to dashboard Cite

ImportanceSome individuals experience persistent symptoms after initial symptomatic SARS-CoV-2 infection (often referred to as Long COVID).ObjectiveTo estimate the proportion of males and females with COVID-19, younger or older than 20 years of age, who had Long COVID symptoms in 2020 and 2021 and their Long COVID symptom duration.Design, Setting, and ParticipantsBayesian meta-regression and pooling of 54 studies and 2 medical record databases with data for 1.2 million individuals (from 22 countries) who had symptomatic SARS-CoV-2 infection. Of the 54 studies, 44 were published and 10 were collaborating cohorts (conducted in Austria, the Faroe Islands, Germany, Iran, Italy, the Netherlands, Russia, Sweden, Switzerland, and the US). The participant data were derived from the 44 published studies (10 501 hospitalized individuals and 42 891 nonhospitalized individuals), the 10 collaborating cohort studies (10 526 and 1906), and the 2 US electronic medical record databases (250 928 and 846 046). Data collection spanned March 2020 to January 2022.ExposuresSymptomatic SARS-CoV-2 infection.Main Outcomes and MeasuresProportion of individuals with at least 1 of the 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after SARS-CoV-2 infection in 2020 and 2021, estimated separately for hospitalized and nonhospitalized individuals aged 20 years or older by sex and for both sexes of nonhospitalized individuals younger than 20 years of age.ResultsA total of 1.2 million individuals who had symptomatic SARS-CoV-2 infection were included (mean age, 4-66 years; males, 26%-88%). In the modeled estimates, 6.2% (95% uncertainty interval [UI], 2.4%-13.3%) of individuals who had symptomatic SARS-CoV-2 infection experienced at least 1 of the 3 Long COVID symptom clusters in 2020 and 2021, including 3.2% (95% UI, 0.6%-10.0%) for persistent fatigue with bodily pain or mood swings, 3.7% (95% UI, 0.9%-9.6%) for ongoing respiratory problems, and 2.2% (95% UI, 0.3%-7.6%) for cognitive problems after adjusting for health status before COVID-19, comprising an estimated 51.0% (95% UI, 16.9%-92.4%), 60.4% (95% UI, 18.9%-89.1%), and 35.4% (95% UI, 9.4%-75.1%), respectively, of Long COVID cases. The Long COVID symptom clusters were more common in women aged 20 years or older (10.6% [95% UI, 4.3%-22.2%]) 3 months after symptomatic SARS-CoV-2 infection than in men aged 20 years or older (5.4% [95% UI, 2.2%-11.7%]). Both sexes younger than 20 years of age were estimated to be affected in 2.8% (95% UI, 0.9%-7.0%) of symptomatic SARS-CoV-2 infections. The estimated mean Long COVID symptom cluster duration was 9.0 months (95% UI, 7.0-12.0 months) among hospitalized individuals and 4.0 months (95% UI, 3.6-4.6 months) among nonhospitalized individuals. Among individuals with Long COVID symptoms 3 months after symptomatic SARS-CoV-2 infection, an estimated 15.1% (95% UI, 10.3%-21.1%) continued to experience symptoms at 12 months.Conclusions and RelevanceThis study presents modeled estimates of the proportion of individuals with at least 1 of 3 self-reported Long COVID symptom clusters (persistent fatigue with bodily pain or mood swings; cognitive problems; or ongoing respiratory problems) 3 months after symptomatic SARS-CoV-2 infection.

show abstract

Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study

Cited by 547 publications

References 16 publications

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

Epidemiology and organ specific sequelae of post-acute COVID19: A narrative review

Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information

Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021

Contact Info

Product

Resources

About